Dr. John Cush RheumNow
3 years 4 months ago
Methotrexate-induced pneumonitis (0.3% risk) is different than RA-ILD. MTX does not increase odds of RA-ILD. @jeffsparks @UTSW_Rheum https://t.co/JV1CcB0sLP
Dr. John Cush RheumNow
3 years 4 months ago
Japanese cohort study shows Lung cancer is more common in males w/ elder-onset dermatomyositis - risk increased by Smoking, anti-TIF1-γ-Abs and elevated MLR (monocyte to lymphocyte ratio) https://t.co/LlTkiWp7pb https://t.co/Bu9atnI8je
Dr. John Cush RheumNow
3 years 4 months ago
Disease activity increases the risk of future RA-ILD. For every one point increase in DAS28, theres a 35% increase risk of RA-ILD @jeffsparks @UTSW_Rheum https://t.co/P3dNDVanuL
Dr. John Cush RheumNow
3 years 4 months ago
MUC5B is a common genetic variant (~12%) that is strongly assoc w/ IPF, but also RA-ILD (3.1-4.7 fold risk) @jeffsparks @UTSW_Rheum https://t.co/t1Kgmj8a3x
Dr. John Cush RheumNow
3 years 4 months ago
Survival in RA-ILD is reduced (data from two different eras) @jeffsparks @UTSW_Rheum https://t.co/7eGgGnEgwW
Dr. John Cush RheumNow
3 years 4 months ago
Risk of RA-ILD is 15% (or 1 in 6) according to Mayo clinic (Olmstead county) data. @jeffsparks https://t.co/KynitLCsK7
Dr. John Cush RheumNow
3 years 4 months ago
#RA with ILD portends poor outcomes, especially if seropositive. Visiting professor Dr. Jeff sparks @jeffsparks @UTSW_Rheum https://t.co/fbVyDMUm6L
A new Swedish ARTIS registry study of key safety outcomes in rheumatoid arthritis (RA) patients receiving either targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs, including Janus Kinase inhibitors (JAKi)), has been updated and affirms previously held risks.
A retrospective study of cancer patients who developed immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA) shows that biologic DMARDs were more effective than conventional synthetic DMARDs (csDMARDs) in rapid control of arthritis.
Dr. John Cush RheumNow
3 years 4 months ago
Rheumatologist - Work-Life Survey Results
Last week, registered Rheumatologists responded to an email survey regarding work-life balance. The following are the results from 190 respondents - 53% were male (47% female) and 94% were from the USA.
https://t.co/2g7oL6ltAo https://t.co/uYv7sDyO9o
Dr. John Cush RheumNow
3 years 4 months ago
Dr. Megan Clowse discusses the differences in pregnancy planning for men and women with rheumatic disease, with particular focus on medication use. Watch now.
https://t.co/Ine8CdbZR4 https://t.co/7UnanlnQcC
Dr. John Cush RheumNow
3 years 4 months ago
FDA FAERS study of IL-17 inhib & colitis: 388 pts w/ suspected IL-17i assoc. IBD. Median age - 42 yrs; Initial Sxs= diarrhea 91%, Abd pain 58%, bloody diarrhea 51%), & fever 36%, ^WBC 87%; Time to onset=2.9 mos. Time to remission after IL-17i D/C =4 wks https://t.co/adrtUhFj9C https://t.co/61GC5hvzYV
Dr. John Cush RheumNow
3 years 4 months ago
Retrospective study of 42 pts w/ cocaine-induced midline or systemic vasculitis; Current cocaine use common (20/23 + urine tox, including pts who prev. deniedcocaine). Found: septal perfs (75%), oronasal fistula(15%), less(27%) systemic Sxs, 56% PR3-ANCA+https://t.co/z1Z4INRSj5 https://t.co/v9ZyZD1Lrb
Dr. John Cush RheumNow
3 years 4 months ago
With AI and GPT-4... "The cognitive speed limit has just been lifted." - John Nosta https://t.co/mMXos8LLt6 https://t.co/imBfp37J1l
